Showing results (261-270 of 365) with videos related to
Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|July 14, 2009
Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?Kyoung Ha Kim, Jeeyun Lee, Jung-Il Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 15, 2025
Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of viewWoong Ki Park, Seok Jin Nam, Seok Won Kim, et al.Neuro-Oncology|June 14, 2012
Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogramHee Kyung Ahn, Soohyeon Lee, Yeon Hee Park, et al.Breast (Edinburgh, Scotland)|November 4, 2023
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancerNalee Kim, Ji-Yeon Kim, Won Park, et al.The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.Cancers|November 10, 2020
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)Soohyeon Lee, Seock-Ah Im, Gun Min Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast CancerYen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.Pageof 37